Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 3 (March)

1. Radiological surveillance of interval breast cancers in screening programmes.
   Lancet Oncol, 7(3): 259-65. [Abstract] [Full-text]
2. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
   Lancet Oncol, 7(3): 223-9. [Abstract] [Full-text]
3. Postirradiation morphea in a breast cancer patient.
   Breast J, 12(2): 173-6. [Abstract] [Full-text]
4. Ectopic ganglion cyst presenting as a breast lump: a rare case report.
   Breast J, 12(2): 170-2. [Abstract] [Full-text]
5. Synchronous presentation of breast carcinoma with plasmacytoid cytomorphology and multiple myeloma.
   Breast J, 12(2): 165-7. [Abstract] [Full-text]
6. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results.
   Breast J, 12(2): 159-64. [Abstract] [Full-text]
7. Influence of hormone replacement therapy on the accuracy of screening mammography.
   Breast J, 12(2): 154-8. [Abstract] [Full-text]
8. Evaluation of margin status in lumpectomy specimens and residual breast carcinoma.
   Breast J, 12(2): 150-3. [Abstract] [Full-text]
9. Variability in gross and microscopic pathology reporting in excisional biopsies of breast cancer tissue.
   Breast J, 12(2): 145-9. [Abstract] [Full-text]
10. Long-term outcomes after breast conservation therapy for early stage breast cancer in a community setting.
    Breast J, 12(2): 138-44. [Abstract] [Full-text]
11. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast J, 12(2): 130-7. [Abstract] [Full-text]
12. Emotional self-efficacy, stressful life events, and satisfaction with social support in relation to mood disturbance among women living with breast cancer in rural communities.
    Breast J, 12(2): 123-9. [Abstract] [Full-text]
13. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
    Breast J, 12(2): 114-22. [Abstract] [Full-text]
14. Breast cancer risk assessment and prevention: a framework for shared decision-making consultations.
    Breast J, 12(2): 103-13. [Abstract] [Full-text]
15. Status of mammography after the Digital Mammography Imaging Screening Trial: digital versus film.
    Breast J, 12(2): 99-102. [Abstract] [Full-text]
16. Risk of second primary malignancies in women with papillary thyroid cancer.
    Am J Epidemiol, 163(6): 521-7. [Abstract] [Full-text]
17. An ecological study of organochlorine pesticides and breast cancer in rural Victoria, Australia.
    Arch Environ Contam Toxicol, 50(3): 452-61. [Abstract] [Full-text]
18. Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone.
    Int J Cancer, 118(10): 2390-8. [Abstract] [Full-text]
19. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Immunol Lett, 104(1): 146-55. [Abstract] [Full-text]
20. Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
    Int J Cancer, 118(10): 2609-16. [Abstract] [Full-text]
21. Alcohol consumption and mammographic density in a multiethnic population.
    Int J Cancer, 118(10): 2579-83. [Abstract] [Full-text]
22. Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population.
    Int J Cancer, 118(10): 2554-8. [Abstract] [Full-text]
23. Epidemiology and the causes of breast cancer.
    Int J Cancer, 118(10): 2373-8. [Abstract] [Full-text]
24. Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk.
    Int J Cancer, 118(10): 2505-8. [Abstract] [Full-text]
25. Comparative genomic hybridization analysis on male breast cancer.
    Int J Cancer, 118(10): 2455-60. [Abstract] [Full-text]
26. Patterns of symptom distress in older women after surgical treatment for breast cancer.
    Oncol Nurs Forum, 33(2): 327-35. [Abstract] [Full-text]
27. Symptoms, symptom beliefs, and quality of life of older breast cancer survivors: a comparative study.
    Oncol Nurs Forum, 33(2): 315-22. [Abstract] [Full-text]
28. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.
    Oncol Nurs Forum, 33(2): 265-72. [Abstract] [Full-text]
29. Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.
    Oncol Nurs Forum, 33(2): E27-35. [Abstract] [Full-text]
30. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.
    Nucleic Acids Res, 34(5): 1416-26. [Abstract] [Full-text]
31. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer.
    Br J Cancer, 94(5): 672-80. [Abstract] [Full-text]
32. Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients.
    Br J Cancer, 94(5): 681-5. [Abstract] [Full-text]
33. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.
    Br J Cancer, 94(5): 661-71. [Abstract] [Full-text]
34. The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction.
    Breast Cancer Res, 8(1): 402. [Abstract] [Full-text]
35. Recent translational research: stem cells as the roots of breast cancer.
    Breast Cancer Res, 8(1): 103. [Abstract] [Full-text]
36. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.
    Breast Cancer Res, 8(1): R11. [Abstract] [Full-text]
37. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
    Breast Cancer Res, 8(1): R12. [Abstract] [Full-text]
38. Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma.
    BMC Cancer, 6: 38. [Abstract] [Full-text]
39. COX-2 induces IL-11 production in human breast cancer cells.
    J Surg Res, 131(2): 267-75. [Abstract] [Full-text]
40. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate.
    Biochem Biophys Res Commun, 342(4): 1341-51. [Abstract] [Full-text]
41. Impact of a scientific presentation on community treatment patterns for primary breast cancer.
    J Natl Cancer Inst, 98(6): 382-8. [Abstract] [Full-text]
42. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells.
    Mol Cell Biol, 26(7): 2501-10. [Abstract] [Full-text]
43. Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy.
    Cancer Treat Rev, 32(2): 106-18. [Abstract] [Full-text]
44. Hormonal therapy for male breast cancer: A different approach for a different disease.
    Cancer Treat Rev, 32(2): 101-5. [Abstract] [Full-text]
45. Missed opportunities: racial disparities in adjuvant breast cancer treatment.
    J Clin Oncol, 24(9): 1357-62. [Abstract] [Full-text]
46. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy.
    J Clin Oncol, 24(9): 1350-6. [Abstract] [Full-text]
47. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status.
    J Clin Oncol, 24(9): 1342-9. [Abstract] [Full-text]
48. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    J Clin Oncol, 24(9): 1332-41. [Abstract] [Full-text]
49. Breast cancer sagittal/horizontal plane location influences axillary lymph node involvement.
    Eur J Surg Oncol, 32(3): 287-91. [Abstract] [Full-text]
50. 5-Year follow-up of sentinel node negative breast cancer patients.
    Eur J Surg Oncol, 32(3): 282-6. [Abstract] [Full-text]
51. Results of sentinel node biopsy not affected by previous excisional biopsy.
    Eur J Surg Oncol, 32(3): 278-81. [Abstract] [Full-text]
52. Estrogenic effects in vitro and in vivo of the fungicide fenarimol.
    Toxicol Lett, 163(2): 142-52. [Abstract] [Full-text]
53. Expression profiling of estrogen-responsive genes in breast cancer cells treated with alkylphenols, chlorinated phenols, parabens, or bis- and benzoylphenols for evaluation of estrogenic activity.
    Toxicol Lett, 163(2): 130-41. [Abstract] [Full-text]
54. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort.
    Int J Cancer, 118(11): 2832-9. [Abstract] [Full-text]
55. Evaluation of RAD50 in familial breast cancer predisposition.
    Int J Cancer, 118(11): 2911-6. [Abstract] [Full-text]
56. Polymorphisms in the growth hormone receptor: a case-control study in breast cancer.
    Int J Cancer, 118(11): 2903-6. [Abstract] [Full-text]
57. Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy.
    Int J Cancer, 118(11): 2877-81. [Abstract] [Full-text]
58. The Salzburg concept of intraoperative radiotherapy for breast cancer: results and considerations.
    Int J Cancer, 118(11): 2882-7. [Abstract] [Full-text]
59. Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival.
    Int J Cancer, 118(11): 2678-84. [Abstract] [Full-text]
60. Are mammotropic hormones mainly permissive for the development of breast cancer?
    Int J Cancer, 118(11): 2863-5. [Abstract] [Full-text]
61. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
    Int J Cancer, 118(11): 2703-10. [Abstract] [Full-text]
62. Extra-tumoral breast tissue in breast cancer patients: variations with steroid contraceptive use.
    Int J Cancer, 118(11): 2827-31. [Abstract] [Full-text]
63. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    JAMA, 295(12): 1379-88. [Abstract] [Full-text]
64. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.
    Br J Cancer, 94(6): 828-34. [Abstract] [Full-text]
65. Association of ginseng use with survival and quality of life among breast cancer patients.
    Am J Epidemiol, 163(7): 645-53. [Abstract] [Full-text]
66. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice.
    Carcinogenesis, 27(4): 856-63. [Abstract] [Full-text]
67. ADH3 genotype, alcohol intake and breast cancer risk.
    Carcinogenesis, 27(4): 840-7. [Abstract] [Full-text]
68. IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project.
    Carcinogenesis, 27(4): 758-65. [Abstract] [Full-text]
69. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population.
    Carcinogenesis, 27(4): 766-71. [Abstract] [Full-text]
70. Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study.
    Carcinogenesis, 27(4): 820-5. [Abstract] [Full-text]
71. Pregnancy-associated breast cancer and metastasis.
    Nat Rev Cancer, 6(4): 281-91. [Abstract] [Full-text]
72. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study.
    BMJ, 332(7543): 689-92. [Abstract] [Full-text]
73. Experimental study of the survival of metastatic cancer cells in corneal organ culture.
    Invest Ophthalmol Vis Sci, 47(4): 1339-47. [Abstract] [Full-text]
74. Nitric oxide and hormones in breast cancer: allies or enemies?
    Future Oncol, 2(2): 275-88. [Abstract] [Full-text]
75. Risk prediction models for familial breast cancer.
    Future Oncol, 2(2): 257-74. [Abstract] [Full-text]
76. The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer.
    Future Oncol, 2(2): 247-55. [Abstract] [Full-text]
77. Farnesol induces thyroid hormone receptor (THR) beta1 but inhibits THR-mediated signaling in MCF-7 human breast cancer cells.
    Biochem Biophys Res Commun, 343(1): 239-43. [Abstract] [Full-text]
78. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease.
    Cancer, 106(7): 1443-52. [Abstract] [Full-text]
79. Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies.
    Cancer, 106(7): 1453-61. [Abstract] [Full-text]
80. Factors associated with surgical options for breast carcinoma.
    Cancer, 106(7): 1462-6. [Abstract] [Full-text]
81. Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells.
    Exp Cell Res, 312(7): 974-82. [Abstract] [Full-text]
82. Randomized trial of peer counseling on reproductive health in African American breast cancer survivors.
    J Clin Oncol, 24(10): 1620-6. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.